Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in L'hospitalet De Llobregat – page 42

978 clinical trials in L'hospitalet De Llobregat, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
L'hospitalet De Llobregat at a glance
978
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

978 trials in L'hospitalet De Llobregat

Open in trial search

Malignant melanoma stage IV+1

Not recruiting

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:BioNTech SE

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Breast cancer+1

Not recruiting

Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Novartis Pharma AG

Pneumonia viral

Not recruiting

Study of inhaled interferon beta-1a (SNG001) for treatment of patients with viral lower respiratory tract infections who require mechanical ventilation

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Interferon Beta-1A
  • Sponsor:Synairgen Research Limited

Myasthenia gravis+1

Not recruiting

Study of Descartes-08 compared to placebo in adults with generalized myasthenia gravis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Cartesian Therapeutics Inc.

Urticaria chronic

Not recruiting

Study of BLU-808 tablets compared to placebo in adults with chronic inducible urticaria and chronic spontaneous urticaria

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Blueprint Medicines Corp.

Idiopathic pulmonary fibrosis

Not recruiting

Study of BI 765423 given by intravenous infusion for patients with idiopathic pulmonary fibrosis with or without standard treatment

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim Espana S.A.

Congenital cystic kidney disease

Not recruiting

Study of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:ABBV-CLS-628
  • Sponsor:Calico Life Sciences LLC

Prostate cancer metastatic

Not recruiting

Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Small cell lung cancer

Not recruiting

Study of Durvalumab for Patients with Limited Stage Small Cell Lung Cancer After Chemoradiotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca Farmaceutica Spain S.A.

Bronchopulmonary aspergillosis

Not recruiting

Effectiveness and Safety of Rezafungin in Adults with Chronic Pulmonary Aspergillosis Who Have Limited Treatment Options

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Rezafungin Acetate
  • Sponsor:Mundipharma Research Limited

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in L'hospitalet De Llobregat

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative research focused on vaccine development targeting multiple infectious diseases, including studies on UTI prevention, yellow fever, and RSV protection in adults.

  • UTI Vaccine Safety & Efficacy
  • Yellow Fever Immunization
  • RSV Protection Studies

These trials aim to enhance vaccine effectiveness and improve public health outcomes through preventive measures.

02 Oncology Research

Comprehensive studies exploring new treatments for various types of advanced cancers, with particular focus on targeted therapies and novel drug combinations.

  • Colorectal Cancer Treatment
  • Gastric Cancer Therapies
  • Pancreatic Cancer Interventions

Advanced clinical research investigating innovative approaches to combat various forms of cancer.

03 Transplant Medicine

Groundbreaking research in kidney transplantation, focusing on preventing rejection and improving post-transplant outcomes.

  • Antibody-Mediated Rejection
  • Delayed Graft Function
  • Novel Immunosuppressive Approaches

Studies aimed at enhancing transplant success rates and patient recovery.

04 Autoimmune Conditions

Clinical investigations into treatments for various autoimmune disorders, including innovative therapies for inflammatory conditions.

  • Psoriatic Arthritis Treatment
  • Atopic Dermatitis Management
  • Myasthenia Gravis Therapy

Focused on developing targeted treatments to improve patient quality of life.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.